Cellular metabolism changes in atherosclerosis and the impact of comorbidities.

atherosclerosis cell metabolism comorbidity diabetes fatty acids glycolysis

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2024
Historique:
received: 10 06 2024
accepted: 17 07 2024
medline: 27 8 2024
pubmed: 27 8 2024
entrez: 27 8 2024
Statut: epublish

Résumé

Cell activation and nutrient dysregulation are common consequences of atherosclerosis and its preceding risk factors, such as hypertension, dyslipidemia, and diabetes. These diseases may also impact cellular metabolism and consequently cell function, and the other way around, altered cellular metabolism can impact disease development and progression through altered cell function. Understanding the contribution of altered cellular metabolism to atherosclerosis and how cellular metabolism may be altered by co-morbidities and atherosclerosis risk factors could support the development of novel strategies to lower the risk of CVD. Therefore, we briefly review disease pathogenesis and the principles of cell metabolic pathways, before detailing changes in cellular metabolism in the context of atherosclerosis and comorbidities. In the hypoxic, inflammatory and hyperlipidemic milieu of the atherosclerotic plaque riddled with oxidative stress, metabolism shifts to increase anaerobic glycolysis, the pentose-phosphate pathway and amino acid use. We elaborate on metabolic changes for macrophages, neutrophils, vascular endothelial cells, vascular smooth muscle cells and lymphocytes in the context of atherosclerosis and its co-morbidities hypertension, dyslipidemia, and diabetes. Since causal relationships of specific key genes in a metabolic pathway can be cell type-specific and comorbidity-dependent, the impact of cell-specific metabolic changes must be thoroughly explored

Identifiants

pubmed: 39188527
doi: 10.3389/fcell.2024.1446964
pii: 1446964
pmc: PMC11345199
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1446964

Informations de copyright

Copyright © 2024 Dai, Junho, Schieren, Wollenhaupt, Sluimer, van der Vorst and Noels.

Déclaration de conflit d'intérêts

Author HN is founding shareholder of AMICARE Development GmbH. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Yusang Dai (Y)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.
Physical Examination Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Carolina Victoria Cruz Junho (CVC)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.

Luisa Schieren (L)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.

Julia Wollenhaupt (J)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.

Judith C Sluimer (JC)

Department of Nephrology and Clinical Immunology, University Hospital RWTH Aachen, Aachen, Germany.
Department of Pathology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands.

Emiel P C van der Vorst (EPC)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.
Aachen-Maastricht Institute for Cardiorenal Disease (AMICARE), RWTH Aachen Campus, Aachen, Germany.
Interdisciplinary Centre for Clinical Research (IZKF), RWTH Aachen University, Aachen, Germany.
Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University Munich, Munich, Germany.

Heidi Noels (H)

Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen University, Aachen, Germany.
Aachen-Maastricht Institute for Cardiorenal Disease (AMICARE), RWTH Aachen Campus, Aachen, Germany.
Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands.

Classifications MeSH